Endothelin converting enzyme inhibitors

Details Endothelin converting enzyme inhibitors Endothelin converting enzyme inhibitors

1992-09-29

1994-08-16

Lee, Lester L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 18, 514 19, 530330, 530331, A61K 3702, C07K 506, C07K 508, C07K 510

Patent

active

053387260

ABSTRACT:
Compounds are disclosed which inhibit endothelin converting enzyme. These compounds are useful for treating hypertension, congestive heart failure, myocardial infarction, reperfusion injury, coronary angina, cerebral vasospasm, acute renal failure, non-steroidal antiinflammatory drug induced gastric ulceration, cyclosporin induced nephrotoxicity, endotoxin-induced toxicity, asthma and atherosclerosis.

REFERENCES:
patent: 4855286 (1989-08-01), Wagner et al.
patent: 4981950 (1991-01-01), Masaki et al.

Affiliated with

Also associated with

Rating

Endothelin converting enzyme inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Endothelin converting enzyme inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endothelin converting enzyme inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-951912